Vol 19 - Apr 2026 Evidence for Primary Care
Evidence for Primary Care: the latest evidence from the Trip Database
A summary of some of the most important new documents for primary care that have recently been added to the Trip Database
Cancer, Cardio and Common Sense: Primary Care Evidence Without the Drama
This edition begins with three documents that feel especially relevant to everyday primary care.
First, NICE’s suspected cancer guidance is a reminder that cancer recognition is rarely neat. Symptoms arrive as weight loss, bleeding, bloating, tiredness, cough, pain or simply concern. The guideline gives useful thresholds for investigation and referral, but the bigger message is not to use criteria as a substitute for judgement. If concern remains, safety-net, review, or ask for specialist advice.
Second, the ovarian cancer guideline clarifies the pathway. Primary care detection now sits mainly in NG12, while CG122 focuses on diagnosis and initial management once ovarian cancer is suspected or confirmed. CA125, ultrasound, RMI scoring and MDT referral are the key steps. It is classic pathway medicine: not glamorous, but vital when symptoms can be vague and diagnosis is often delayed.
Third, the AHA dietary statement brings some welcome calm to cardiovascular nutrition. No miracle foods, no dramatic reinvention — just a whole-diet pattern: more vegetables, fruit, whole grains, legumes, nuts, fish and unsaturated fats; less ultra-processed food, added sugar, salt, saturated fat and alcohol. Sensible advice, now with a scientific statement attached.
The rest of the edition keeps the practical tone. Macrolides may modestly improve asthma outcomes, but stewardship still matters. Stable type 2 diabetes may not need HbA1c testing every three months. Teledermatology could help stretched services, provided images and pathways are good. Depression in cancer needs proper assessment and stepped care. Opioid tapering, meanwhile, is not just about dose reduction — it is about trust, fear, stigma and support.
A varied batch, then, but with a common thread: evidence helps most when it supports thoughtful clinical judgement. Primary care is often about knowing when to act quickly, when to monitor carefully, and when doing less may actually be better care.
In This Edition
- When should people with possible cancer symptoms be investigated or referred?
- How should suspected or confirmed ovarian cancer be diagnosed and initially managed?
- What dietary pattern best supports cardiovascular health and reduces CVD risk?
- Do macrolides improve outcomes in people with asthma?
- How often should HbA1c be checked in stable type 2 diabetes?
- How should depression be managed in adults with cancer?
- Can teledermatology improve management of primary care dermatology referrals?
- Does high-dose influenza vaccine reduce cardiovascular outcomes more than standard-dose vaccine in older adults?
- Could GLP-1 receptor agonists help treat alcohol use disorder?
- What interventions improve women’s experience of pelvic examinations?
- Is targeted or population screening for osteoporosis in women effective and cost-effective?
- How should menopause be identified and managed?
- Does oral semaglutide improve cardiovascular risk factors in high-risk type 2 diabetes?
- What interventions safely reduce long-term opioid use in chronic non-cancer pain?
NICE
When should people with possible cancer symptoms be investigated or referred?
Clinical bottom line: NICE NG12 gives primary care thresholds for urgent cancer investigation, suspected cancer referral, or safety-netting. Do not rely only on strict criteria: if concern persists, review, safety-net, or seek specialist advice.
Brief summary: This guideline covers recognition and referral of suspected cancer in children, young people and adults. It is organised by cancer site, symptom, and primary care investigation findings. It sets out when to use urgent tests, suspected cancer pathways, non-specific symptom pathways, and safety-netting.
View ArticleNICE
How should suspected or confirmed ovarian cancer be diagnosed and initially managed?
Clinical bottom line: NICE CG122 covers secondary care diagnosis and initial treatment of ovarian cancer. Primary care detection now sits in NG12; suspected cases need CA125/ultrasound-based assessment, RMI scoring, specialist MDT referral when RMI ≥250, and stage-based surgery/systemic treatment.
Brief summary: The guideline covers women aged 18+ with suspected or confirmed epithelial ovarian, fallopian tube, primary peritoneal, or borderline ovarian cancer. It recommends CA125, ultrasound as first-line imaging, CT for staging when cancer is suspected, and avoiding routine MRI. Management depends on stage: optimal surgical staging for suspected stage 1 disease, adjuvant carboplatin for high-risk stage 1, complete macroscopic resection as the surgical aim in advanced disease, and NICE-approved systemic/maintenance therapies for advanced or relapsed disease.
View ArticleAmerican Heart Association
What dietary pattern best supports cardiovascular health and reduces CVD risk?
Clinical bottom line: The AHA recommends a whole-diet pattern, not single “superfoods” or nutrients: maintain healthy weight, eat plenty of varied fruit/veg and whole grains, favour plant proteins, fish, low-fat dairy and unsaturated fats, and minimise ultra-processed foods, added sugars, sodium and alcohol.
Brief summary: This 2026 AHA statement updates dietary advice for cardiovascular health across the life course. Heart-healthy patterns include DASH, Mediterranean-style, pescetarian and vegetarian diets when well constructed. The guidance emphasises practical, food-based choices: replace saturated fats with non-tropical plant oils, shift protein away from red/processed meat towards legumes, nuts and fish, choose whole rather than refined grains, reduce sugary drinks and salt, and do not start drinking alcohol for heart health.
View ArticleJ Allergy Clin Immunol.
Do macrolides improve outcomes in people with asthma?
Clinical bottom line: Macrolides modestly improve asthma control and probably reduce severe exacerbations, with little evidence of increased serious adverse events. Benefits appear similar in type 2-high and type 2-low asthma, but antibiotic stewardship and resistance remain important considerations.
Brief summary: This systematic review included 19 randomised trials with 1,825 participants. Compared with placebo, macrolides improved asthma control by a small amount, reduced severe exacerbations by about 25% relative, and may slightly improve quality of life. There was little or no difference in serious adverse events or mortality. Evidence certainty was high for asthma control and serious harms, and moderate for exacerbations and quality of life.
View ArticleTherapeutics Initiative
How often should HbA1c be checked in stable type 2 diabetes?
Clinical bottom line: For people with stable type 2 diabetes who are meeting glycaemic goals, HbA1c testing every 6 months is likely sufficient; 3-monthly testing adds little. Test more often when treatment is changing, targets are unmet, or health status is unstable.
Brief summary: This Therapeutics Letter reviewed one RCT and three large observational studies. In the RCT, 6-monthly testing maintained good control as well as 3-monthly testing. Observational data also found no clinically meaningful advantage to testing every 3 months. The article cautions against over-interpreting small HbA1c changes because of biological and laboratory variability; testing is most useful when the result is likely to change management.
View ArticleCancer Care Ontario
How should depression be managed in adults with cancer?
Clinical bottom line: Adults with cancer should be screened for depression, assessed for severity and suicide risk, and treated using a stepped-care approach. Mild/moderate depression generally starts with psychosocial support; more severe or persistent depression may need antidepressants, specialist input, or collaborative care.
Brief summary: This Cancer Care Ontario/PEBC guideline covers adults with cancer and diagnosed or suspected depressive disorder. It recommends confirming depression, excluding medical contributors such as thyroid disease, B12/folate deficiency or anaemia, optimising cancer-related symptoms, and using validated scales to monitor response. Treatment may include psychoeducation, psychological therapies, antidepressants, collaborative care, and specialist referral when risk, complexity, diagnostic uncertainty or non-response is present.
View ArticleHIQA
Can teledermatology improve management of primary care dermatology referrals?
Clinical bottom line: Store-and-forward teledermatology could help Ireland manage dermatology demand by improving triage, reducing face-to-face appointments, shortening waits, and lowering missed appointments. It appears broadly safe, but diagnostic accuracy varies and depends on image quality, clinician experience, and appropriate pathways.
Brief summary: This HIQA HTA found that teledermatology-supported referral management is likely to improve efficiency in overstretched dermatology services. Most evidence supports store-and-forward models, where GPs send images with referral information for dermatologist review. Evidence suggests moderate-to-high triage concordance, generally comparable management decisions, fewer face-to-face appointments, and likely cost savings. Implementation would need good imaging, electronic referral infrastructure, training, clear governance, patient consent, and safeguards to avoid incentivising avoidance of clinically needed face-to-face review.
View ArticleCirculation
Does high-dose influenza vaccine reduce cardiovascular outcomes more than standard-dose vaccine in older adults?
Clinical bottom line: In adults aged 65+, high-dose influenza vaccine modestly reduced cardiovascular and respiratory hospitalisations compared with standard-dose vaccine, with similar benefit whether or not people had pre-existing cardiovascular disease. The clearest cardiovascular signal was fewer heart failure hospitalisations.
Brief summary: This prespecified pooled analysis combined two pragmatic randomised trials from Denmark and Spain, including 466,320 older adults. Compared with standard-dose vaccine, high-dose vaccine reduced hospitalisation for any cardiovascular disease, respiratory disease, influenza/pneumonia, laboratory-confirmed influenza and all-cause hospitalisation. Heart failure hospitalisation was reduced most notably: 0.11% vs 0.15%, relative vaccine effectiveness 21.3%.
View ArticleClinical Correlations
Could GLP-1 receptor agonists help treat alcohol use disorder?
Clinical bottom line: GLP-1 receptor agonists such as semaglutide are a promising but still experimental option for alcohol use disorder. Early human evidence suggests reduced alcohol craving and heavy drinking, but current data are too limited to replace established AUD treatments.
Brief summary: This article reviews the rationale for using GLP-1 receptor agonists in addiction: these drugs act not only on appetite and metabolism, but also on brain reward pathways. Animal studies show reduced alcohol intake and relapse-like drinking, while observational studies link GLP-1 use with fewer alcohol-related hospitalisations. A small phase II RCT of semaglutide in adults with AUD found reductions in heavy drinking and craving. Larger, longer trials are needed to confirm benefits, define who benefits most, and clarify safety in people with psychiatric comorbidity.
View ArticleBJOG
What interventions improve women’s experience of pelvic examinations?
Clinical bottom line: Simple measures may reduce pain and anxiety during pelvic examinations, but the evidence is heterogeneous. These interventions fit well with trauma-informed care, but stronger studies are needed.
Brief summary: This systematic review included 16 RCTs with 4,641 women. Most studies tested procedural, environmental or cognitive approaches to improve the examination experience. Pooled results showed reductions in pain and anxiety, but heterogeneity was very high and several studies had risk-of-bias concerns, so confidence in the size of benefit is limited.
View ArticleNIHR
Is targeted or population screening for osteoporosis in women effective and cost-effective?
Clinical bottom line: The evidence base for osteoporosis screening in women is limited. Existing reviews largely rely on the same small number of primary studies, so uncertainty remains about the effectiveness, cost-effectiveness and equity impact of targeted or population screening.
Brief summary: This scoping review found 19 studies, including 3 RCTs, related sibling papers, one cohort study and six reviews. Most focused on women aged 65+ and used risk assessment tools and/or DXA scanning. Outcomes mainly included fractures, quality of life and cost-effectiveness. The review concluded that evidence is sparse and gives limited attention to equity-related factors such as age, income, education and relationships.
View ArticleNICE
How should menopause be identified and managed?
Clinical bottom line: NICE NG23 recommends diagnosing menopause clinically in most people aged 45+ with typical symptoms, without routine blood tests. Management should be individualised, with HRT offered for vasomotor symptoms when suitable, vaginal oestrogen for genitourinary symptoms, and CBT considered for vasomotor symptoms, sleep problems or depressive symptoms.
Brief summary: This guideline covers identification and management of menopause, including premature ovarian insufficiency. It emphasises shared decision-making, tailored discussion of HRT benefits and risks, use of the lowest effective HRT dose, review after starting treatment, and specialist input for complex situations such as breast cancer history, high VTE risk, previous coronary disease or stroke, or premature ovarian insufficiency.
View ArticleJAMA Cardiol.
Does oral semaglutide improve cardiovascular risk factors in high-risk type 2 diabetes?
Clinical bottom line: In high-risk adults with type 2 diabetes and ASCVD and/or CKD, once-daily oral semaglutide produced early and sustained improvements in several cardiovascular risk factors, including HbA1c, weight, systolic blood pressure, inflammation and triglycerides, on top of standard care.
Brief summary: This post hoc analysis of the SOUL RCT included 9,650 participants followed for about 4 years. Compared with placebo, oral semaglutide improved HbA1c, body weight, systolic blood pressure, pulse pressure, hsCRP, total cholesterol, non-HDL cholesterol and triglycerides. There was no significant difference in LDL cholesterol or diastolic blood pressure. The parent SOUL trial also reported a 14% reduction in major adverse cardiovascular events with oral semaglutide.
View ArticleNIHR
What interventions safely reduce long-term opioid use in chronic non-cancer pain?
Clinical bottom line: Evidence for specific opioid tapering interventions is mixed and uncertain. Tapering should be individualised, relationship-based, and supported by attention to fear, stigma, pain control, mental health and relapse risk.
Brief summary: This systematic review included 44 studies on interventions to reduce or stop prescribed opioids in adults with chronic non-cancer pain. Most studies reported reduced opioid use, but interventions were heterogeneous and evidence was not strong enough to identify a best approach. Pain generally did not worsen versus controls, serious adverse events were not reported, and acceptability evidence was limited. Barriers included behavioural, structural and contextual factors, with possible poorer tapering outcomes in men and older patients.
View Article
